streptococcal polysaccharide type III group B

01/01/2019 - "We further investigated the efficacy of an anti-CCL24 monoclonal antibody (mAb), CM-101, in inhibiting cell activation as well as dermal and pulmonary inflammation and fibrosis in experimental animal models. "
01/01/2018 - "Conclusion CM-101 demonstrated fast blood clearance and whole-body elimination, negligible accumulation of gadolinium in bone or tissue, and robust detection of fibrosis in rat BDL and mouse CCl4 models of liver fibrosis. "
01/01/2023 - "CCL24-neutralizing monoclonal antibody, CM-101, significantly improved inflammation, fibrosis, and cholestasis-related markers in the biliary area. "
01/01/2020 - "To evaluate the prognostic value of posttreatment fibrosis in human PDAC patients, and to compare a type I collagen targeted MRI probe, CM-101, to the standard contrast agent, Gd-DOTA, for their abilities to identify FOLFIRINOX-induced fibrosis in a murine model of PDAC. "

01/01/1998 - "CM101 has successfully completed phase I studies in refractory cancer patients with very encouraging results. "
01/01/2020 - "CM-101 MR signal was significantly increased in fibrotic tumor regions. "
10/15/2000 - "CM101 induced loss of tumor immunoprivilege through changes in the expression of leukocyte p53, tumor Fas and fasL coupled with neovascularitis and leukocyte infiltration, constitutes a plausible molecular pathway for tumor reduction observed in cancer patients."
10/15/2000 - "Collectively, these data suggest that CM101 up-regulates p53 in tumor-infiltrating leukocytes, initiating a loss of tumor immunoprivilege and consequently rendering the tumor sensitive to Fas/fasL-mediated apoptosis. "
10/15/2000 - "CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis."

01/01/2019 - "In BLM-induced experimental animal models, CM-101 profoundly inhibited both dermal and pulmonary fibrosis and inflammation. "
10/15/2000 - "Data from refractory cancer patients in a Phase I clinical trial with CM101 indicated a similar mechanism of tumor-targeted inflammation. "
03/01/1997 - "The results show that CM101 can be safely administered at doses that produce evidence for severe, and possibly tumor-specific, inflammation. "
03/01/1997 - "CM101 is a bacterial polysaccharide that induces neovascular inflammation in malignant tumors. "
01/01/2023 - "CCL24-neutralizing monoclonal antibody, CM-101, significantly improved inflammation, fibrosis, and cholestasis-related markers in the biliary area. "

01/01/2019 - "We further investigated the efficacy of an anti-CCL24 monoclonal antibody (mAb), CM-101, in inhibiting cell activation as well as dermal and pulmonary inflammation and fibrosis in experimental animal models. "

01/01/2023 - "CCL24-neutralizing monoclonal antibody, CM-101, significantly improved inflammation, fibrosis, and cholestasis-related markers in the biliary area. "